TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35615627
Drug: Structured active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured active play intervention (combined in-hospital and home-based program, 45-min sessions three times weekly)
Study: 35615718
Drug: rATG (rabbit
Approvals — FDA: no, EMA: no, PMDA: no
Description: rATG (rabbit antithymocyte globulin) administered intravenously at a dose of 0.8-1.0 mg/kg daily (cumulative dose of 150-200 mg)
Study: 35616437
Drug: Repetitive task
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repetitive task practice using a combination of robot-assisted therapy and functional arm use in real-world tasks
Study: 35617646
Drug: CTC enumeration
Normalized name: CTCE-0214
DrugBank: CTCE-0214 (DB05934)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTC enumeration trajectory in the highest quartile (> 0.12 CTCs/mL annually)
Study: 35618839
Drug: Pembrolizumab combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab combined with low-dose cyclophosphamide
Study: 35619189
Drug: Nebulized haMSC-Exos
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized haMSC-Exos (2.0 × 10^6 exosomes daily for 5 days)
Study: 35619611
Drug: Transdermal trigeminal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal trigeminal electrical neuromodulation (TTEN) for 4 weeks, daily 20 min sessions
Study: 35619611
Drug: Transdermal trigeminal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal trigeminal electrical neuromodulation (TTEN)
Study: 35620522
Drug: Nicotinamide riboside
Normalized name: Nicotinamide riboside
DrugBank: Nicotinamide riboside (DB14933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide riboside (500 mg, 2×/day)
Study: 35622082
Drug: Pancreatic enzyme
Normalized name: Pancreatic enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatic enzyme medication (Creon)
Study: 35622315
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) 400 mg every 2 weeks (Q2W)
Study: 35623855
Drug: Iron deficiency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron deficiency (SF < 15.0 μg/L)
Study: 35623855
Drug: Iron insufficiency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron insufficiency (SF < 20.0 μg/L)
Study: 35623855
Drug: Iron insufficiency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron insufficiency (SF < 25.0 μg/L)
Study: 35623855
Drug: Iron deficiency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron deficiency anemia (IDA) (Hb < 12.0 g/dL and SF < 15.0 μg/L)
Study: 35623855
Drug: Anemia (Hb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anemia (Hb < 12.0 g/dL)
Study: 35623855
Drug: Severe anemia
Normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe anemia (Hb < 8.0 g/dL)
Study: 35623855
Drug: C-reactive protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-reactive protein (CRP > 5.0 mg/L)
Study: 35623855
Drug: Alpha-1 acid
Normalized name: Alpha-1 acid glycoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-1 acid glycoprotein (AGP > 1.0 g/L)
Study: 35623976
Drug: Information and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information and therapy guides
Study: 35624056
Drug: Oral combination
Normalized name: clozapine ORAL COMBINATION PACKAGE (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral combination of VTS-Aspirin and ketamine (mean ketamine dose 37.8 mg, range 24 mg to 50 mg)
Study: 35624056
Drug: Oral combination
Normalized name: clozapine ORAL COMBINATION PACKAGE (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral combination of VTS-Aspirin and ketamine
Study: 35624418
Drug: Dexmedetomidine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine at a dose of 0.5 μg/kg, adjusted in 0.1 μg/kg gradients based on previous patient outcomes.
Study: 35626701
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of human immature dental pulp stem cells (hIDPSC)
Study: 35627709
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of oral anticoagulants
Study: 35627709
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of antiarrhythmic and diuretic agents
Study: 35628832
Drug: Chronic OAC
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic OAC (various types including rivaroxaban, dabigatran, apixaban, and vitamin K antagonists)
Study: 35632416
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of live attenuated varicella vaccine (VarV) administered 1 year after primary immunization (Group 1)
Study: 35632416
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of live attenuated varicella vaccine (VarV) administered 2 years after primary immunization (Group 2)
Study: 35632416
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of live attenuated varicella vaccine (VarV) administered 3 years after primary immunization (Group 3)
Study: 35633970
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of autologous thymic-derived regulatory T cells (thyTreg)
Study: 35634171
Drug: Photothermal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photothermal therapy
Study: 35634417
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of a dietary multi-ingredient nootropic
Study: 35634506
Drug: Irisin serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irisin serum levels in CMT patients (6.51 ± 2.26 μg/ml)
Study: 35634506
Drug: Irisin serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irisin serum levels in CMT patients with pathological muscle strength (5.56 ± 1.26 μg/ml)
Study: 35634506
Drug: Irisin levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irisin levels in women (7.31 ± 2.53 μg/ml)
Study: 35635640
Drug: Afatinib 40
Normalized name: afatinib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib 40 mg daily until disease progression or unacceptable toxicity
Study: 35635644
Drug: Iodine-containing supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodine-containing supplements (ICS)
Study: 35635644
Drug: No iodine-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: No iodine-containing supplements (non-users)
Study: 35635728
Drug: Tiotropium /
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium / olodaterol combination treatment
Study: 35635746
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy and smartphone-based National Cancer Institute QuitGuide app
Study: 35636792
Drug: Volume of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume of first 24-hours blood product administration
Study: 35636921
Drug: Erlotinib 350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 350 mg once weekly for 6 months
Study: 35637081
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PNI and serum sodium level
Study: 35639457
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g daily collagen peptide supplement
Study: 35639644
Drug: mRNA (BNT162b2)
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA (BNT162b2) vaccine
Study: 35639825
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg intravenously once every 21 days in cohort 1 (n = 8)
Study: 35639825
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg intravenously once every 21 days in cohort 2 (n = 4)
Study: 35639825
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg intravenously once every 21 days in cohort 3 (n = 9)
Study: 35639922
Drug: Dexamethasone (DXM)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DXM) treatment in CARDS patients
Study: 35640276
Drug: UGN-102 (mitomycin-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: UGN-102 (mitomycin-containing reverse thermal gel), 6 weekly instillations
Study: 35640276
Drug: UGN-102 (mitomycin-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: UGN-102 (mitomycin-containing reverse thermal gel)
Study: 35640474
Drug: NLG207 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: NLG207 12 mg/m2 in combination with enzalutamide
Study: 35640864
Drug: Community-based pelvic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based pelvic floor physical therapy
Study: 35640864
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of BET with squeeze duration (BET > 6.5 seconds and limited squeeze duration)
Study: 35641194
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of phylloquinone thrice weekly
Study: 35641481
Drug: Camrelizumab 200
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Camrelizumab 200 mg (day 1), Apatinib 250 mg daily, Eribulin 1.4 mg/m²
Study: 35641780
Drug: Itraconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (200 mg) with milvexian (30 mg)
Study: 35641780
Drug: Diltiazem (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (240 mg) with milvexian (30 mg)
Study: 35642431
Drug: ABBV-011 (calicheamicin-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABBV-011 (calicheamicin-based antibody-drug conjugate)
Study: 35643089
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (300 mg orally once a day from the 24th week of gestation until 6 weeks postpartum)
Study: 35643571
Drug: Concentric LV
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concentric LV remodeling in T2D (mass/volume 0.91±0.15 g/mL)
Study: 35643589
Drug: BEMPEG 0.006
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEMPEG 0.006 mg/kg plus nivolumab 360 mg intravenously every 3 weeks
Study: 35643624
Drug: Palbociclib plus
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib plus an aromatase inhibitor (PAL+AI) initiated at 125 mg/d
Study: 35643624
Drug: Palbociclib plus
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib plus an aromatase inhibitor (PAL+AI) initiated at 75/100 mg/d
Study: 35643624
Drug: Palbociclib plus
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib plus an aromatase inhibitor (PAL+AI)
Study: 35646641
Drug: High-dose methotrexate-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate-based treatment
Study: 35647062
Drug: Sequential Multi-Point
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Multi-Point Pacing
Study: 35647711
Drug: Danuglipron (PF-06882961),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danuglipron (PF-06882961), an orally bioavailable small-molecule GLP-1R agonist, administered orally.
Study: 35647908
Drug: sintilimab 200
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sintilimab 200 mg every 3 weeks (21 patients), 1 mg/kg every 2 weeks (2 patients), 3 mg/kg every 2 weeks (1 patient)
Study: 35647938
Drug: G/nab-P
Approvals — FDA: no, EMA: no, PMDA: no
Description: G/nab-P
Study: 36701676
Drug: Allergen Immunotherapy
Normalized name: Allergen immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen Immunotherapy
Study: 35650616
Drug: Higher cumulative
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher cumulative fluid balance (median 1.98 L)
Study: 35650616
Drug: Intermediate cumulative
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate cumulative fluid balance (median 0.78 L)
Study: 35650616
Drug: Lower cumulative
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower cumulative fluid balance (median -0.35 L)
Study: 35650617
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity on prescription (PAP) intervention
Study: 35651792
Drug: BCMA CAR-T
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCMA CAR-T cell therapy
Study: 35651792
Drug: Previous treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous treatments (bortezomib, Adriamycin, dexamethasone, lenalidomide, daratumumab)
Study: 35651818
Drug: Different sequenced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different sequenced pharmacotherapy options
Study: 35651818
Drug: SSRIs (first-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRIs (first-line pharmacotherapy)
Study: 35652112
Drug: Methylprednisolone 40
Normalized name: methylprednisolone 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 40 mg during the first CPR cycle and hydrocortisone 240 mg daily for 7 days maximum (steroids group)
Study: 35652820
Drug: Nonfermented dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonfermented dairy intake (each 100-g increase)
Study: 35653029
Drug: OC-01 VNS
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC-01 VNS (0.06 mg)
Study: 36280870
Drug: SHR-1701 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1701 at 30 mg/kg every 3 weeks
Study: 35653138
Drug: HPV vaccination
Normalized name: HPV-16 trojan peptide vaccine
DrugBank: HPV-16 trojan peptide vaccine (DB17496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccination as an adjuvant treatment
Study: 35653552
Drug: 5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg monovalent HepB vaccine
Study: 35654732
Drug: Epitinib 120
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Epitinib 120 mg QD
Study: 35654732
Drug: Epitinib 160
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Epitinib 160 mg QD
Study: 35655320
Drug: FGF401 (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: FGF401 (120 mg qd)
Study: 35655320
Drug: FGF401 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FGF401 plus spartalizumab (FGF401 120 mg qd and spartalizumab 300 mg Q3W)
Study: 35655320
Drug: FGF401 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: FGF401 (50 to 150 mg)
Study: 35656720
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (TT: 1 anticoagulant and 2 antiplatelet agents)
Study: 35656720
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (1 anticoagulant + 1 antiplatelet agent)
Study: 35656931
Drug: Oral anticoagulants
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulants for treating AF
Study: 35657428
Drug: Gallium-68-labeled fibroblast
Normalized name: Gallium 68 dotatate
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallium-68-labeled fibroblast activation protein inhibitor PET
Study: 35657653
Drug: PF-06747775 monotherapy
Normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06747775 monotherapy at recommended Phase 2 dose (200 mg QD)
Study: 35657653
Drug: PF-06747775 200
Normalized name: acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PF-06747775 200 mg QD plus palbociclib (100 mg QD orally)
Study: 35657653
Drug: PF-06747775 monotherapy
Normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06747775 monotherapy at RP2D in a Japanese lead-in cohort
Study: 35657979
Drug: Pembrolizumab+chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab+chemotherapy
Study: 37099736
Drug: Adagrasib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adagrasib (600 mg orally twice daily)
Study: 35658469
Drug: Ciltacabtagene autoleucel
Normalized name: ciltacabtagene autoleucel
DrugBank: Ciltacabtagene autoleucel (DB16738)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciltacabtagene autoleucel (cilta-cel) infusion after lymphodepletion
Study: 35659282
Drug: Intravenous tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous tocilizumab (TCZ) 7 mg/kg Q4W
Study: 35659282
Drug: Intravenous tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous tocilizumab (TCZ) 6 mg/kg Q4W
Study: 35659282
Drug: Intravenous tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous tocilizumab (TCZ) 8 mg/kg Q4W (previous treatment)
Study: 35659581
Drug: Limertinib 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limertinib 160 mg orally twice daily
Study: 35660797
Drug: Dostarlimab (anti-PD-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dostarlimab (anti-PD-1 monoclonal antibody), administered every 3 weeks for 6 months
Study: 35663154
Drug: Subcutaneous tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous tocilizumab (TCZ) therapy
Study: 35663767
Drug: 7.5% urea
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5% urea cream
Study: 35663767
Drug: Basic moisturizer
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic moisturizer (vehicle cream)
Study: 35664443
Drug: Single-dose Vi-DT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose Vi-DT (n=252)
Study: 35665739
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of autologous total IgG (50 mg, 8 injections over 4 weeks)
Study: 35667016
Drug: Befovacimab 100
Normalized name: Befovacimab
DrugBank: Befovacimab (DB16188)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Befovacimab 100 mg
Study: 35667016
Drug: Befovacimab 225
Normalized name: Befovacimab
DrugBank: Befovacimab (DB16188)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Befovacimab 225 mg
Study: 35667016
Drug: Befovacimab 400
Normalized name: Befovacimab
DrugBank: Befovacimab (DB16188)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Befovacimab 400 mg
Study: 35667016
Drug: Befovacimab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Befovacimab (all doses)
Study: 35667271
Drug: Nutritional Quality
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional Quality Improvement Program (QIP) including education, dietary counseling, and oral nutritional supplements (ONS) for daily intake over 60 days.
Study: 35667399
Drug: Telehealth physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telehealth physical therapy (PT)
Study: 35667558
Drug: BNT162b2 vaccine
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 vaccine or mRNA-1273 vaccine, administered in two or three doses
Study: 35667724
Drug: Remote self-administered
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remote self-administered speech tasks
Study: 35669398
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (10 mg/kg/day for 3 days)
Study: 35669398
Drug: Intravenous immunoglobulins
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulins (IVIG) (2 g/kg as a single dose)
Study: 35671038
Drug: Tralokinumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tralokinumab (300 mg) administered subcutaneously every 4 weeks
Study: 35671108
Drug: Guadecitabine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guadecitabine (30 mg/m2) on days 1-4, and pembrolizumab (200 mg i.v.) on day 5, every 21 days
Study: 35671201
Drug: Tremelimumab 3
Normalized name: TREMELIMUMAB 300 mg in 15 mL INTRAVENOUS INJECTION, SOLUTION [IMJUDO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab 3 or 10 mg/kg (Q4W for 6 doses/Q12W thereafter until discontinuation)
Study: 35671201
Drug: Tremelimumab 10
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab 10 mg/kg (Q4W for 6 doses/Q12W for 3 doses) plus durvalumab 15 mg/kg (Q4W for 13 doses)
Study: 35671201
Drug: Tremelimumab 1
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab 1 mg/kg (Q4W for 4 doses) plus durvalumab 20 mg/kg (Q4W for 4 doses followed by 10 mg/kg Q2W for 22 doses)